An overview of the John Theurer Cancer Center at Hackensack University Medical Center - a top-50 U.S. News & World Report Best Hospitals for Cancer – the only cancer center in New Jersey with this prestigious designation.
To request printed copies of this brochure, please contact aleahing@p4strategy.com.
Nov. Webinar - Research Update: advanced adenomas among first degree relative...Fight Colorectal Cancer
Fight CRC has funded Dr. Christine Molmenti from Northwell Health and Dr. Heather Hampel from The Ohio State University Comprehensive Cancer Center to research the feasibility of determining advanced adenoma(s) history among first degree relatives of early onset colorectal cancer patients. In this month's webinar, Dr. Molmenti and Andrea (Andi) Dwyer from Fight CRC and University of Colorado, will explain why the research is important, how Fight CRC is involved, and how the results could have clinical implications.
This document is a curriculum vitae for Dr. Mao-Bin Meng. It lists his educational background, including medical degrees from Sichuan University and a Ph.D. in Radiation Biology. It details his professional experience, including current appointments as an Associate Professor at Tianjin Medical University Cancer Institute and previous roles. It also lists research funding he has received and publications, including papers in peer-reviewed journals.
The document provides an overview of the history and development of oncology. It discusses how cancer was first documented in ancient Egypt and treated by cauterization. It then covers key developments like Hippocrates naming cancer, the first autopsy being performed in 1761, and the establishment of the TNM staging system. The summary concludes by briefly mentioning common modern cancer treatment modalities like surgery, radiation therapy, chemotherapy, and their goals of cure, palliation, or prevention.
Paris Saint-Joseph Hospital offers a comprehensive multimodality of care for patients with a broad variety of cancers. The goal is to offer high level of technics and technology while offering humanized approaches.
Downloadable slides highlighting key concepts in colorectal cancer screening and appropriate therapy selection and application in the adjuvant setting and beyond.
Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.
This document provides recommendations for transplanting organs from deceased donors with cancer or a history of cancer. It finds that:
1) Organs from donors with some cancers may be safely transplanted, with the risk of cancer transmission needing to be balanced against risks to recipients who do not receive transplants.
2) The risk of donor-transmitted cancer in the UK is currently 0.06%, with most cases able to be treated.
3) Donors' cancers can be categorized as absolutely contraindicated, higher risk, or lower risk based on characteristics summarized in tables. Informed consent is crucial given risks.
Nov. Webinar - Research Update: advanced adenomas among first degree relative...Fight Colorectal Cancer
Fight CRC has funded Dr. Christine Molmenti from Northwell Health and Dr. Heather Hampel from The Ohio State University Comprehensive Cancer Center to research the feasibility of determining advanced adenoma(s) history among first degree relatives of early onset colorectal cancer patients. In this month's webinar, Dr. Molmenti and Andrea (Andi) Dwyer from Fight CRC and University of Colorado, will explain why the research is important, how Fight CRC is involved, and how the results could have clinical implications.
This document is a curriculum vitae for Dr. Mao-Bin Meng. It lists his educational background, including medical degrees from Sichuan University and a Ph.D. in Radiation Biology. It details his professional experience, including current appointments as an Associate Professor at Tianjin Medical University Cancer Institute and previous roles. It also lists research funding he has received and publications, including papers in peer-reviewed journals.
The document provides an overview of the history and development of oncology. It discusses how cancer was first documented in ancient Egypt and treated by cauterization. It then covers key developments like Hippocrates naming cancer, the first autopsy being performed in 1761, and the establishment of the TNM staging system. The summary concludes by briefly mentioning common modern cancer treatment modalities like surgery, radiation therapy, chemotherapy, and their goals of cure, palliation, or prevention.
Paris Saint-Joseph Hospital offers a comprehensive multimodality of care for patients with a broad variety of cancers. The goal is to offer high level of technics and technology while offering humanized approaches.
Downloadable slides highlighting key concepts in colorectal cancer screening and appropriate therapy selection and application in the adjuvant setting and beyond.
Join your peers and colleagues in San Francisco to gain insight and perspective on why molecular liquid biopsies have the potential to become a fulcrum in the future of precision medicine.
This document provides recommendations for transplanting organs from deceased donors with cancer or a history of cancer. It finds that:
1) Organs from donors with some cancers may be safely transplanted, with the risk of cancer transmission needing to be balanced against risks to recipients who do not receive transplants.
2) The risk of donor-transmitted cancer in the UK is currently 0.06%, with most cases able to be treated.
3) Donors' cancers can be categorized as absolutely contraindicated, higher risk, or lower risk based on characteristics summarized in tables. Informed consent is crucial given risks.
The document is the NCCN Clinical Practice Guidelines in Oncology for Pancreatic Adenocarcinoma from 2009. It provides guidelines for the diagnosis, staging, treatment and management of pancreatic cancer. The guidelines are developed by the NCCN Pancreatic Adenocarcinoma Panel and are intended to help clinicians individualize treatment for each patient based on clinical circumstances.
Importance of circulating tumour cells in patients with non-metastatic breast...Senology.org
The study found that the presence of circulating tumor cells (CTCs) in patients with early-stage breast cancer carried a higher risk of cancer recurrence or death. Patients with one or more CTCs had a four times greater risk, and those with three or more CTCs faced an 11.5 times higher risk of death from breast cancer. CTC levels did not correlate with lymph node status or primary tumor characteristics, suggesting CTC measurement provides additional prognostic information beyond standard analysis. However, larger studies are still needed to determine how best to use CTC information in clinical decision-making.
Medooc is a search engine for researching medical information.It has been built by medical
professionals to help others in the community to research and share credible health information.
Doctors, Physcials and medical professionals participate in Medooc.com on day to day basis to help
each other.
For more information you can visit:-http://www.medooc.com/
This document provides an overview of oropharyngeal squamous cell carcinoma. It discusses the background, risk factors, diagnosis, staging, treatment options, and nutritional considerations for this type of head and neck cancer. A case study is presented of a 62-year-old male patient diagnosed with oropharyngeal cancer who underwent chemotherapy and radiation treatment. He experienced significant weight loss but was able to regain weight through enteral nutrition support via a PEG tube. His cancer is now in remission. The document also reviews several research studies on links between diet and cancer risk/outcomes.
There are many types of cancer treatment that depend on the type and stage of cancer, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplants, and precision medicine. Surgery attempts to remove the entire tumor mass and sometimes lymph nodes, while radiation therapy uses radiation to damage cancer cell DNA. Chemotherapy uses cytotoxic drugs to kill rapidly dividing cells, and can be used with other treatments. Targeted therapy and immunotherapy target specific molecular differences in cancer cells. Hormone therapy slows the growth of cancers that use hormones, and stem cell transplants restore blood-forming stem cells after other treatments destroy them. Precision medicine selects individualized treatments based on the genetics of a patient's cancer.
This study assessed the prognostic value of lymph node ratio (LNR) and extramural vascular invasion (EMVI) in predicting survival outcomes for 922 patients who underwent curative colon cancer resection between 2006-2012. The results showed that both increasing LNR and presence of EMVI were independently associated with decreased overall and disease-free survival on multivariate analysis. LNR was found to have greater prognostic value compared to the current pN staging system based on Akaike information criterion. Subgroup analysis by EMVI status also confirmed LNR and EMVI as significant predictors of survival.
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
This document discusses the diagnosis and management of choledocholithiasis (CBD stones). Key points include:
- CBD stones occur in 3-10% of patients undergoing cholecystectomy and may be discovered preoperatively, intraoperatively, or postoperatively.
- Preoperative evaluation involves laboratory tests, ultrasound, CT, and MRCP to detect CBD stones. Elevated liver enzymes and bilirubin or a dilated CBD on imaging increase the likelihood of stones.
- The most common intervention for CBD stones is ERCP. Other options include intraoperative exploration or percutaneous transhepatic removal of stones. The optimal timing and approach depends on the individual clinical situation.
This study evaluated the epidemiology and treatment outcomes of advanced gastric cancer in Jordan. The study compared outcomes for patients treated with two chemotherapy regimens - DCF (docetaxel, cisplatin, fluorouracil) and ECF (epirubicin, cisplatin, fluorouracil). Results showed that the DCF regimen had a higher response rate and longer time to tumor progression, but similar median survival times. Characteristics of gastric cancer patients in Jordan were similar to high-risk areas, with most cases occurring in older males. This study provides useful data on gastric cancer in the Middle East.
Chemotherapy 'vastly underutilized' in bladder cancerYael Waknine
A major weapon in the armamentarium against bladder cancer — neoadjuvant chemotherapy (NACT) — is rarely used in clinical practice, according to a large population study published online April 14 in Cancer.
Researchers analyzed 2944 patient records from the Ontario Cancer Registry, and found that a mere 4% of patients, on average, received standard-of-care NACT prior to cystectomy for muscle-invasive bladder cancer from 1994 to 2008.
Surprisingly, the popularity of adjuvant chemotherapy (ACT) rose over the same period; it was 16% from 1994 to 1998, 18% from 1999 to 2003, and 22% from 2004 to 2008.
Moreover, the controversial ACT was linked to benefits deemed "probably on the same order of magnitude" as NACT (all-cause mortality hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.62 - 0.81; cancer-related HR, 0.73; 95% CI, 0.64 - 0.84), after relevant patient- and disease-related characteristics were controlled for.
Objective: Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography screening can reduce lung cancer–specific mortality by 20%.
This meta-analysis examined outcomes of limb-salvage surgery (LSS) versus amputation for osteosarcoma. It found:
1) LSS had better functional outcomes than amputation.
2) The 5-year overall survival rate was higher for patients who received LSS than amputation.
3) There was no significant difference in local recurrence rates between LSS and amputation.
Cancer is characterized by uncontrolled cell growth and spread. Some key points:
- Lung cancer is the most common cancer in men and breast cancer is most common in women.
- Risk factors include tobacco use, obesity, viruses, chemicals, radiation, and genetic mutations.
- Prevention focuses on healthy behaviors like not smoking, diet, exercise and limiting sun exposure.
- Treatment involves surgery, radiation, chemotherapy and other approaches depending on cancer type and stage. Combined therapies are often used but all treatments can cause side effects.
Aboriginal Patterns of Cancer Care Project Breast Cancer paper BMCCancer 1471...Cancer Council NSW
Aboriginal women in New South Wales, Australia have lower rates of survival from breast cancer than non-Aboriginal women. Aboriginal women were less likely to receive surgical treatment for their breast cancer and were more likely to have other health issues. After accounting for differences in factors like age, disease stage at diagnosis, surgical treatment, and health issues, Aboriginal women still had a 30% higher risk of death from breast cancer. Improving access to surgical treatment and reducing health issues may help increase breast cancer survival rates for Aboriginal women.
Oral cancer is a term used for cancers occurring in the oral cavity. It is the most common type of head and neck cancer. Risk factors for oral cancer include tobacco use, heavy alcohol consumption, human papillomavirus infection, and sun exposure. Data from the SEER program shows that from 2002-2006 the age-adjusted incidence of oral cancer in the United States was 10.4 per 100,000 people, while the age-adjusted mortality rate was 2.6 per 100,000. Survival rates are lower for advanced stage cancers, cancers in black males, and HPV-negative tonsillar cancers.
Learning about health, family history and what information to collect is important! As we prepare for November as Health History Month, the holidays provide an excellent opportunity for families to share health history. This webinar will help you learn about colorectal cancer and cancer diagnosis, and what this means for you and your family. We’ll give you tools and resources that help you collect this important information.
http://fightcolorectalcancer.org/get-resources/webinar-series/
Pancreatic cancer - But the visionary digital leader had been battling pancreatic cancer since 2004. Pancreatic cancer is one of the faster spreading cancers; only about 4% of patients can expect to survive five years after their diagnosis. Each year, about 44000 new ...
This document summarizes recent developments in the treatment of immune thrombocytopenia (ITP). It discusses new evidence on treatments for refractory ITP including rituximab, thrombopoietin receptor agonists (TPO-RAs), and long-term use of eltrombopag. A randomized controlled trial found that rituximab did not significantly reduce long-term treatment failure compared to placebo in previously steroid-treated ITP patients. Long-term use of eltrombopag for up to 3 years was found to be generally safe and effective at maintaining platelet counts. The document concludes that large, randomized studies are still needed to better understand new ITP treatment options and balancing risks versus benefits requires consideration
Robert Orlowski is a professor of myeloma/lymphoma at MD Anderson Cancer Center who has published extensively on cancer therapy. His research focuses on translating promising laboratory findings into clinical trials for hematologic malignancies. The document summarizes several of his presentations and studies on new treatments for multiple myeloma and other plasma cell dyscrasias, including studies on carfilzomib, lenalidomide, and other novel agents alone and in combination for newly diagnosed, relapsed/refractory, and amyloidosis patients. It discusses efficacy and safety results and the changing treatment landscape in these diseases.
The document is the NCCN Clinical Practice Guidelines in Oncology for Pancreatic Adenocarcinoma from 2009. It provides guidelines for the diagnosis, staging, treatment and management of pancreatic cancer. The guidelines are developed by the NCCN Pancreatic Adenocarcinoma Panel and are intended to help clinicians individualize treatment for each patient based on clinical circumstances.
Importance of circulating tumour cells in patients with non-metastatic breast...Senology.org
The study found that the presence of circulating tumor cells (CTCs) in patients with early-stage breast cancer carried a higher risk of cancer recurrence or death. Patients with one or more CTCs had a four times greater risk, and those with three or more CTCs faced an 11.5 times higher risk of death from breast cancer. CTC levels did not correlate with lymph node status or primary tumor characteristics, suggesting CTC measurement provides additional prognostic information beyond standard analysis. However, larger studies are still needed to determine how best to use CTC information in clinical decision-making.
Medooc is a search engine for researching medical information.It has been built by medical
professionals to help others in the community to research and share credible health information.
Doctors, Physcials and medical professionals participate in Medooc.com on day to day basis to help
each other.
For more information you can visit:-http://www.medooc.com/
This document provides an overview of oropharyngeal squamous cell carcinoma. It discusses the background, risk factors, diagnosis, staging, treatment options, and nutritional considerations for this type of head and neck cancer. A case study is presented of a 62-year-old male patient diagnosed with oropharyngeal cancer who underwent chemotherapy and radiation treatment. He experienced significant weight loss but was able to regain weight through enteral nutrition support via a PEG tube. His cancer is now in remission. The document also reviews several research studies on links between diet and cancer risk/outcomes.
There are many types of cancer treatment that depend on the type and stage of cancer, including surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy, hormone therapy, stem cell transplants, and precision medicine. Surgery attempts to remove the entire tumor mass and sometimes lymph nodes, while radiation therapy uses radiation to damage cancer cell DNA. Chemotherapy uses cytotoxic drugs to kill rapidly dividing cells, and can be used with other treatments. Targeted therapy and immunotherapy target specific molecular differences in cancer cells. Hormone therapy slows the growth of cancers that use hormones, and stem cell transplants restore blood-forming stem cells after other treatments destroy them. Precision medicine selects individualized treatments based on the genetics of a patient's cancer.
This study assessed the prognostic value of lymph node ratio (LNR) and extramural vascular invasion (EMVI) in predicting survival outcomes for 922 patients who underwent curative colon cancer resection between 2006-2012. The results showed that both increasing LNR and presence of EMVI were independently associated with decreased overall and disease-free survival on multivariate analysis. LNR was found to have greater prognostic value compared to the current pN staging system based on Akaike information criterion. Subgroup analysis by EMVI status also confirmed LNR and EMVI as significant predictors of survival.
Background: The incidence of cancers is increasing worldwide, particularly in the developing countries as shown by recent cancer stastics from the WHO. It is even anticipated that with the increase in life expentancy, consequent upon inproved standard of living and globalization, the burden of cancers will increase within this millenium. With respective to cancer of the prostate, it is the most common type of cancer in urology. In developing countries, diagnostic is done at a late stage of evolution. In Cameroon, data on prostate cancer are scanty whereas the incidence of this disease is increasing. Objective: This article is designed to describe the epidemiological features of prostate cancer at the General Hospital of Yaoundé. Patients and methods: A 4-year retrospective study of patients seen with the diagnosis of cancer at the Medical Oncology unit of the Yaoundé General Hospital between January 2012 and December 2015. The demographic pattern (age of patients, socio professional activity, marital status), clinical features (cancer diagnosis), treatment modalities and outcome were studied. Main results: Of the 7 775 patients enrolled in the Medical Oncology Service over the study period, 1.4% (n = 108) cases of prostate cancer were seen. The prevalence over the study period was 1.38% and a relatively large annual growth of cases with an annual average of 27 cases was noted. The average age of patients was 67.82 years with a range of 34-83 years. The commonest presenting symptoms were the urinary frequency (54.63%) whereas the least common were fatigue (05.5%) and straining (03.70%). PSA was obtained in 49 patients, representing about 45.4% of all patients. Only 14 (01.26%) had biopsy reports. Conclusion: Prostate cancer is a major problem facing the aging male, and inadequate facilities make early detection difficult. Therefore, treatment is mainly palliative because of late diagnosis.
This document discusses the diagnosis and management of choledocholithiasis (CBD stones). Key points include:
- CBD stones occur in 3-10% of patients undergoing cholecystectomy and may be discovered preoperatively, intraoperatively, or postoperatively.
- Preoperative evaluation involves laboratory tests, ultrasound, CT, and MRCP to detect CBD stones. Elevated liver enzymes and bilirubin or a dilated CBD on imaging increase the likelihood of stones.
- The most common intervention for CBD stones is ERCP. Other options include intraoperative exploration or percutaneous transhepatic removal of stones. The optimal timing and approach depends on the individual clinical situation.
This study evaluated the epidemiology and treatment outcomes of advanced gastric cancer in Jordan. The study compared outcomes for patients treated with two chemotherapy regimens - DCF (docetaxel, cisplatin, fluorouracil) and ECF (epirubicin, cisplatin, fluorouracil). Results showed that the DCF regimen had a higher response rate and longer time to tumor progression, but similar median survival times. Characteristics of gastric cancer patients in Jordan were similar to high-risk areas, with most cases occurring in older males. This study provides useful data on gastric cancer in the Middle East.
Chemotherapy 'vastly underutilized' in bladder cancerYael Waknine
A major weapon in the armamentarium against bladder cancer — neoadjuvant chemotherapy (NACT) — is rarely used in clinical practice, according to a large population study published online April 14 in Cancer.
Researchers analyzed 2944 patient records from the Ontario Cancer Registry, and found that a mere 4% of patients, on average, received standard-of-care NACT prior to cystectomy for muscle-invasive bladder cancer from 1994 to 2008.
Surprisingly, the popularity of adjuvant chemotherapy (ACT) rose over the same period; it was 16% from 1994 to 1998, 18% from 1999 to 2003, and 22% from 2004 to 2008.
Moreover, the controversial ACT was linked to benefits deemed "probably on the same order of magnitude" as NACT (all-cause mortality hazard ratio [HR], 0.71; 95% confidence interval [CI], 0.62 - 0.81; cancer-related HR, 0.73; 95% CI, 0.64 - 0.84), after relevant patient- and disease-related characteristics were controlled for.
Objective: Lung cancer is the leading cause of cancer death in North America. Low-dose computed tomography screening can reduce lung cancer–specific mortality by 20%.
This meta-analysis examined outcomes of limb-salvage surgery (LSS) versus amputation for osteosarcoma. It found:
1) LSS had better functional outcomes than amputation.
2) The 5-year overall survival rate was higher for patients who received LSS than amputation.
3) There was no significant difference in local recurrence rates between LSS and amputation.
Cancer is characterized by uncontrolled cell growth and spread. Some key points:
- Lung cancer is the most common cancer in men and breast cancer is most common in women.
- Risk factors include tobacco use, obesity, viruses, chemicals, radiation, and genetic mutations.
- Prevention focuses on healthy behaviors like not smoking, diet, exercise and limiting sun exposure.
- Treatment involves surgery, radiation, chemotherapy and other approaches depending on cancer type and stage. Combined therapies are often used but all treatments can cause side effects.
Aboriginal Patterns of Cancer Care Project Breast Cancer paper BMCCancer 1471...Cancer Council NSW
Aboriginal women in New South Wales, Australia have lower rates of survival from breast cancer than non-Aboriginal women. Aboriginal women were less likely to receive surgical treatment for their breast cancer and were more likely to have other health issues. After accounting for differences in factors like age, disease stage at diagnosis, surgical treatment, and health issues, Aboriginal women still had a 30% higher risk of death from breast cancer. Improving access to surgical treatment and reducing health issues may help increase breast cancer survival rates for Aboriginal women.
Oral cancer is a term used for cancers occurring in the oral cavity. It is the most common type of head and neck cancer. Risk factors for oral cancer include tobacco use, heavy alcohol consumption, human papillomavirus infection, and sun exposure. Data from the SEER program shows that from 2002-2006 the age-adjusted incidence of oral cancer in the United States was 10.4 per 100,000 people, while the age-adjusted mortality rate was 2.6 per 100,000. Survival rates are lower for advanced stage cancers, cancers in black males, and HPV-negative tonsillar cancers.
Learning about health, family history and what information to collect is important! As we prepare for November as Health History Month, the holidays provide an excellent opportunity for families to share health history. This webinar will help you learn about colorectal cancer and cancer diagnosis, and what this means for you and your family. We’ll give you tools and resources that help you collect this important information.
http://fightcolorectalcancer.org/get-resources/webinar-series/
Pancreatic cancer - But the visionary digital leader had been battling pancreatic cancer since 2004. Pancreatic cancer is one of the faster spreading cancers; only about 4% of patients can expect to survive five years after their diagnosis. Each year, about 44000 new ...
This document summarizes recent developments in the treatment of immune thrombocytopenia (ITP). It discusses new evidence on treatments for refractory ITP including rituximab, thrombopoietin receptor agonists (TPO-RAs), and long-term use of eltrombopag. A randomized controlled trial found that rituximab did not significantly reduce long-term treatment failure compared to placebo in previously steroid-treated ITP patients. Long-term use of eltrombopag for up to 3 years was found to be generally safe and effective at maintaining platelet counts. The document concludes that large, randomized studies are still needed to better understand new ITP treatment options and balancing risks versus benefits requires consideration
Robert Orlowski is a professor of myeloma/lymphoma at MD Anderson Cancer Center who has published extensively on cancer therapy. His research focuses on translating promising laboratory findings into clinical trials for hematologic malignancies. The document summarizes several of his presentations and studies on new treatments for multiple myeloma and other plasma cell dyscrasias, including studies on carfilzomib, lenalidomide, and other novel agents alone and in combination for newly diagnosed, relapsed/refractory, and amyloidosis patients. It discusses efficacy and safety results and the changing treatment landscape in these diseases.
Carfilzomib: new standard of care for myelomaspa718
Carfilzomib is a second-generation proteasome inhibitor that is highly selective and irreversible. Studies show it has minimal off-target effects and less neurotoxicity compared to other proteasome inhibitors like bortezomib. Single agent and combination studies demonstrated high response rates in relapsed multiple myeloma patients, including those with high-risk cytogenetics or renal impairment. Phase 3 trials showed carfilzomib combinations had improved progression-free and overall survival compared to standards of care. Ongoing studies are exploring carfilzomib in frontline multiple myeloma treatment.
This document discusses multiple myeloma, a plasma cell disorder. It begins with an overview of plasma cell disorders and defines multiple myeloma. It then covers the epidemiology, etiology, pathophysiology, clinical features, diagnostic tests including serum protein electrophoresis and immunofixation, bone marrow examination, skeletal survey, staging, prognostic factors. It also discusses related conditions like monoclonal gammopathy of undetermined significance, smoldering myeloma, non-secretory myeloma, solitary plasmacytoma, extramedullary plasmacytoma. It concludes with discussing criteria for diagnosing multiple myeloma and initial treatment approaches.
Multiple myeloma is a cancer of plasma cells that results in excessive numbers of abnormal plasma cells in the bone marrow. It is characterized by overproduction of monoclonal proteins, known as M proteins, and can cause symptoms such as anemia, kidney damage, and bone fractures. Diagnosis involves blood and urine tests to detect M proteins, bone marrow biopsy to identify plasma cell percentage, and imaging tests to check for bone lesions. Treatment may include chemotherapy, steroids, stem cell transplantation, and other newer drugs depending on the stage of disease and patient health. The goals of treatment are to eliminate the myeloma, control disease activity, and relieve symptoms in order to prolong survival and quality of life.
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...James Prudhomme
This document provides information about a two-day hematologic cancers training program taking place in Newark, NJ in October 2017. The program will review the hematological system and provide an overview of hematologic cancers such as leukemias, lymphomas and myeloma. Experts will discuss the pathophysiology, common treatments, management challenges and complications like bone marrow transplant. Case studies and discussion are included. The program is intended for pharmaceutical and biotech personnel. Topics will include blood cell formation/maturation, cancer classification/epidemiology, diagnosis/staging, chemotherapy and clinical trials.
The document provides updates from various departments at the Kimmel Cancer Center. It announces new treatments for prostate cancer including high intensity focused ultrasound. It highlights advances in areas like radiation oncology, integrative medicine, and stem cell research. It recognizes support from donors and announces new rankings for cancer care.
The document provides an update on the progress and accomplishments of the Nemours Center for Childhood Cancer Research (NCCCR). Key points include:
- NCCCR has established collaborations with other institutions to integrate childhood cancer research efforts and leverage resources to become a national leader.
- Major accomplishments include establishing monthly research translation meetings between clinicians and researchers, and creating one of the few pediatric tumor banks in the US to facilitate biomarker discovery.
- The vision is to develop strategies to advance childhood cancer screening, diagnosis, treatment and prevention, with a focus on identifying biomarkers, developing drug delivery approaches, and discovering new drugs.
The Asian Fund for Cancer Research is a nonprofit organization headquartered in Hong Kong that is committed to curing cancers that significantly impact Asian populations. It focuses on investigating cancers' causes in Asia and developing more effective therapies tailored for Asian patients. AFCR bridges scientific gaps in cancer research between Asia and the rest of the world by promoting international collaboration and funding projects. It supports multiple research programs investigating prevention strategies, early detection technologies, new drugs, and traditional Chinese medicines for cancers like lung, esophageal, and colorectal cancers.
The document summarizes the state of cancer research in 2010 according to the Campbell Family Cancer Research Institute. Key points include:
- Significant advances have been made in understanding the genetic and epigenetic basis of cancer and tumor behavior. However, cures require strategies to destroy both bulk tumor cells and tumor-initiating cells.
- The immune system plays an important role in preventing tumors, but tumors evade immunity; immunotherapies aim to reactivate anti-tumor immune responses.
- Early detection through improved imaging techniques can increase cure rates for cancers caught at smaller sizes.
BASIC PRINCIPLES OF CANCER CHEMOTHERAPY- THIRD PHARM.DAPOLLO JAMES
Oncology pharmacists can play important roles in cancer care like optimizing medication use and participating in clinical trials. They are involved in all aspects of care from chemotherapy preparation to patient education. Education and training are needed to prepare pharmacists for their role in the multidisciplinary cancer care team where they work to ensure safe, effective, and cost-effective drug therapy for patients.
Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric CancersLAB IDEA
This chapter discusses tumor markers for liver cancer. Liver cancer, or hepatocellular carcinoma, is a major cause of cancer death worldwide. Early detection is important for effective treatment but many cases are asymptomatic and detected late. The guidelines evaluate tumor markers like alpha-fetoprotein for surveillance of high-risk patients and diagnosis of liver cancer, noting their limitations. Recommendations are provided on the appropriate use of tumor markers in conjunction with imaging for managing liver cancer.
The Beijing Tiantan Puhua Hospital is the largest neuroscience specialty hospital in Beijing. It was originally a joint venture ward within the renowned Tiantan Hospital but opened as an independent hospital in 2005. It operates in conjunction with American, Chinese, and other international partners. The hospital utilizes international standards and facilities alongside experts from China's top hospitals to provide comprehensive neuroscience and other healthcare services. It is also a leader in neural stem cell research and treatment.
Larkin Community Hospital provides a wide range of medical services to the South Miami community. It has 146 beds and specializes in medical, surgical, psychiatric and teaching services. It also has outpatient clinics and is accredited by the Joint Commission. The hospital focuses on healthcare reform initiatives to improve care and reduce costs. It is also committed to graduate medical education, training new physicians through residency programs in family medicine, internal medicine, and psychiatry.
This document is the 2012 annual report for UPMC CancerCenter and University of Pittsburgh Cancer Institute. It highlights three key points:
1. UPMC CancerCenter brings together physicians, researchers, and staff from across the region to provide comprehensive cancer services through its large network of centers.
2. The report summarizes accomplishments in 2012, including new facilities like the Mario Lemieux Center for Blood Cancers, clinical trials, and international partnerships.
3. UPMC CancerCenter's leadership expresses pride in the organization's progress and anticipation for continued scientific advances that will improve cancer care and work towards eliminating the disease.
- The Personalized OncoGenomics (POG) program at the British Columbia Cancer Agency conducted whole-genome analysis on tumors from 100 patients with advanced or incurable cancers to inform treatment decisions.
- Fresh tumor and blood samples were obtained from patients and underwent whole-genome and RNA sequencing. Computational analysis identified potential driver mutations, genes and pathways.
- A multidisciplinary team discussed genomic findings weekly and established guidelines for interpreting and communicating results to integrate them into patient care. Genomic findings were considered actionable in 55 of 78 cases that underwent whole-genome analysis, and motivated treatment changes in 23 cases.
- The experience demonstrated that a multidisciplinary team can implement an approach where whole-genome
The document summarizes an update on the Emory Eye Tumor SPORE (Specialized Programs of Research Excellence), which aims to advance research on ocular melanoma through collaboration between basic and clinical scientists. It describes the origins and goals of the SPORE program and the Emory Eye Tumor SPORE in particular. The Emory SPORE has added conjunctival malignant melanoma to its research focus. It provides details on the principal investigators, projects, and scoring of the SPORE grant application to the NIH, noting strengths in significance, innovation, investigators, and environment.
This document provides an overview of cancer basics for patient navigators. It begins with acknowledgements and lists competencies covered, which include demonstrating familiarity with cancer screening, diagnosis, treatment and survivorship. It then covers learning objectives such as understanding cancer, screening options, basic treatment types, supportive care services and using professional resources. The document provides information on cancer causes, risk factors, prevention, signs and symptoms, detection methods, staging systems, treatment types including surgery, radiation, chemotherapy and targeted therapy. It also discusses palliative care, complementary therapies and important resources for evidence-based cancer information.
The document summarizes an article from The LANCET Oncology journal about the epidemiology of breast cancer. It includes details about the journal such as its impact factor and indexing. The summary highlights that breast cancer risk is associated with factors that increase estrogen exposure like early menarche and late menopause. Childbearing and breastfeeding may reduce risk. While only a minority of cases are linked to gene mutations, changes to modifiable risk factors like obesity and alcohol consumption could lower breast cancer incidence. The conclusion states that identifying new lifestyle risk factors and chemoprevention trials may further progress in battling breast cancer.
This chapter discusses the anatomy and histology of the anus. There are several ways to define the boundaries of the anal canal, including anatomically from the dentate line to the anal verge, pathologically as the area between the upper and lower borders of the anal sphincter complex, and surgically as the area between the pelvic floor and anoderm. The anal canal has both squamous and columnar epithelial cells and is innervated by sacral nerves S2-S4. Understanding the anatomy of the anus is important for appropriately staging and treating anal cancer.
The 10 Most Impactful Leaders in Life Science.pdfTHECIOWORLD
This edition features a handful of The Most Impactful Leaders in Life Science that are leading us into a better future
Read More: https://thecioworld.com/the-10-most-impactful-leaders-in-life-science-september2023/
This document summarizes an upcoming Cancer Diagnosis & Therapy Congress organized by MnM Conferences on September 3-4, 2015 in London. The two-day conference will bring over 150 experts from around the world to discuss advances in cancer diagnosis technologies and novel targeted cancer therapies. Key discussion topics will include interventional radiology techniques, immunotherapy, biomarkers, nanotechnology, biosensors, and functional genomics. Over 30 distinguished international speakers will present, including researchers from industry, academia, and hospitals. The conference aims to provide a platform for knowledge sharing between researchers, pharmaceutical companies, and doctors to collaborate and stay updated on the latest discoveries and technologies for cancer diagnosis and treatment.
Recent developments in cancer and covid 19tazib rahaman
The document discusses several recent studies on COVID-19. It describes how a study found no link between hypertension drugs and increased COVID-19 risk. It also discusses how a study in Wuhan detected genetic material of the coronavirus in airborne particles, reinforcing the importance of sterilization and ventilation. Additionally, it mentions a new drug candidate identified by Chinese scientists that inhibits a key part of the virus's machinery.
Global Academic Program of MD Anderson Cancer Centerspa718
The Global Academic Programs (GAP) at MD Anderson Cancer Center supports the institution's mission of eliminating cancer globally through its Sister Institution Network of 33 cancer centers in 24 countries. GAP facilitates collaboration between MD Anderson and its sister institutions across key areas of patient care, research, prevention, and education. Notable activities include referring international patients for second opinions and treatment through the Sister Institution Referral Assistance Center, funding collaborative research projects through the Sister Institution Network Fund, increasing global cancer publications and clinical trials, implementing tobacco control programs, and convening an annual conference to foster networking.
Similar to John Theurer Cancer Center at Hackensack University Medical Center (20)
This document discusses white foods and their nutritional value. It summarizes that while colorful foods contain many nutrients, white foods should not be avoided and contain important nutrition as well. Examples of healthy white foods provided are potatoes, cauliflower, beans, mushrooms, and onions. The document then provides recipes for a potato soup, white bean spread, and kasha pilaf with mushrooms to showcase nutritious white food options.
This document summarizes a nutrition discussion and cooking demonstration that featured three healthy appetizer recipes: Cranberry Chicken Salad Cups made with wonton skins, Mini Spanakopitas which are low-fat Greek spinach pies, and Garbanzo Guacamole which combines beans and avocado. The demonstration emphasized making party foods that are both tasty and healthy by using ingredients like egg whites instead of whole eggs, baking wonton skins instead of frying, and reducing fat and calories in the recipes. Detailed instructions and nutrition information are provided for each of the three appetizer recipes.
This document provides recipes for two savory side dishes - a Savory Bread Pudding with Swiss Chard and a Wild Rice Pilaf with Cranberries and Pecans. The bread pudding uses stale bread, Swiss chard, cheese, herbs and eggs baked into a creamy dish. The pilaf combines wild rice, stock, shallots, dried fruits and toasted pecans for a flavorful grain side. Instructions for preparing both dishes are included.
A chef from Whole Foods Market demonstrated how to use various whole grains like brown rice, wheat berries, and pearled barley in meals. She shared recipes for breakfast porridge made with brown rice, a wheat berry and apricot salad, and a barley pilaf. Whole grains provide more fiber and nutrients than processed grains and have a nutty taste and chewy texture. The chef provided tips for incorporating more whole grains into meals easily.
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise causes chemical changes in the brain that may help protect against mental illness and improve symptoms.
The document provides recipes for Southwest Stew, Babaganoush, and Chocolate Haystacks to serve at a Super Bowl party. The Southwest Stew is a hearty vegetarian chili-like dish made with tomatoes, vegetables, chickpeas and spinach. Babaganoush is a roasted eggplant dip made with tahini, lemon juice and olive oil. Chocolate Haystacks are a fiber-rich dessert made by coating a high-fiber cereal with dark chocolate and peanut butter, then adding dried fruit. The recipes allow for preparations in advance so the host is not busy during the game.
Evelyn Margolin from Whole Foods Market in Ridgewood visited a cooking studio to demonstrate how to make traditional Passover Seder menu items vegan. She used recipes from Vegan Holiday Kitchen to modify dishes like matzo ball soup, vegetable kugel, and coconut almond macaroons to eliminate animal products and comply with Kosher for Passover restrictions. The matzo balls were made with quinoa flakes instead of eggs. The vegetable kugel contained mushrooms for texture and potato starch instead of eggs. Coconut almond macaroons used potato starch instead of egg whites for leavening. The dishes were flavorful and satisfying for the vegan Passover Seder.
This document provides a recipe for Irish soda bread along with context about the cultural history and variations of Irish soda bread. It discusses how there is no single authentic recipe as versions vary between Ireland and America. The winner of a soda bread baking contest was John Napoli's entry using his great-grandmother's recipe passed down to him. The document also provides the full recipe for Great-Grandma Henrehan's Irish soda bread and a strawberry rhubarb compote recipe to serve alongside.
This document provides recipes for two immune-boosting soups - Greek Avgolemono Soup and Shiitake Hot and Sour Soup - that can help protect against colds and flu. It discusses how foods like vitamin C, zinc, garlic and ginger have immune-boosting properties. The soups contain ingredients like chicken broth, eggs, tofu and vegetables that are nourishing and may help ease symptoms. Directions are included for making both easy and flavorful soup recipes.
This document announces an interactive evening event about multiple myeloma featuring speaker Dr. David H. Vesole. The event will be held on February 28, 2013 from 6-7:30 PM at Gilda's Club Northern New Jersey and will include a presentation on myeloma disease management and treatment options, followed by a question and answer session and stories from myeloma survivors. Pre-registration is required by February 26th.
2. John Theurer Cancer Center
One of the Nation’s
Top 50 Cancer Centers
For the past 25 years, John Theurer Cancer Center
at Hackensack University Medical Center has
become one of the largest and most comprehensive
cancer centers in the United States. Today, we are
a top-50 U.S. News & World Report Best Hospitals
for Cancer – the only cancer center in New Jersey
with this prestigious designation.
jtcancercenter.org
201-996-5900
3. message A Message from Dr. Pecora and Dr. Goy
At the John Theurer Cancer Center, we believe cancer is hard enough for patients and their loved ones.
It is this belief that drives our passion to deliver extraordinary care every day, helping us become one of the
nation’s top 50 cancer centers – the only cancer center in New Jersey with this recognition.
Over the past 25 years, we have become one of the largest cancer centers in the United States, but we have
kept our focus on the unique needs of the patients who place their trust in our doctors and staff. Prevention,
treatment, and research advances have grown exponentially over those 25 years. We are not only keeping
up with the change of pace, we are at the forefront of delivering innovative care, and providing tomorrow’s
treatment today by:
• Taking multidisciplinary care to a new level with teams of disease-specific experts under one roof
• Delivering personalized medicine focused on novel therapies, participatory treatment, predictive
measures, and preventive care
• Advancing research through biomarker-driven clinical trials and translational research
• Providing holistic care that includes a wide range of complementary services important to the
well-being of our patients that can be easily integrated into their care
• Creating a comforting environment in a new high-tech, high-touch building
We believe our model is the next step toward the future of patient care. In the pages that follow, we invite
you to see how the John Theurer Cancer Center is changing the cancer care experience one patient at a time.
Sincerely,
Andrew Pecora, M.D., F.A.C.P., C.P.E. Andre Goy, M.D., M.S.
Chief Innovations Officer, Professor and
Chairman and Director, Chief of Lymphoma, and
Vice President of Cancer Services, John Theurer Director, Clinical and Translational Cancer Research,
Cancer Center at Hackensack University Medical Center John Theurer Cancer Center at Hackensack University
Medical Center
4. facilities A New Building to Deliver Extraordinary Care
In January 2011, we opened a new building that now houses our 14 specialty divisions along with our
research and oncology services. This provides our patients with an unparalleled experience through
innovative approaches in comfortable surroundings.
Innovative Care in a Patient-Centered Environment
The lobby features a flight of 200 soaring Murano glassblown birds and an inspiring Living Wall made of over
30 plant species, all hydroponically growing without soil and accompanied by a 24-foot waterfall. The wall
breaks down indoor air contaminates through entirely natural processes, releasing purer, cleaner air.
Other resources to help patients and caregivers in their fight against cancer include:
• Tranquility/meditation room, fitness studio, and yoga classes that are free for patients
• Terrace garden with a vegetable garden to teach cancer patients how to grow their own food
• Patient resource library with a medical librarian and cyber café to stay connected
• Demonstration kitchen for cooking and nutrition lessons
jtcancercenter.org
5. John Theurer Cancer Center Practice Specialties
We are comprised of 14 specialized divisions and Radiation Oncology experts.
Division Chiefs are supported by medical, research, nursing, nutrition, and
psychosocial support for more advanced, focused care for patients.
Blood and Marrow Stem Cell Geriatric Oncology Division
Transplantation Program
Head and Neck Oncology Division
Lymphoma Division
Thoracic Oncology Division
Multiple Myeloma Division
Radiation Oncology Department
Leukemia Division
Urologic Oncology Division
Neuro-Oncology Division:
Brain and Spine Institute Breast Oncology Division
Skin and Sarcoma Division: Gynecologic Oncology Division
Cutaneous Malignancy Program
Research Division
Gastrointestinal Oncology
Division
specialties
6. Hematological Malignancies
Our clinicians are leading some of the most significant research for blood-borne
Lymphoma
cancers today. In 2010, we presented research updates and clinical trial results of Andre Goy, M.D., M.S., Chairman and Director, Chief, Lymphoma and Director, Clinical and Translational Cancer Research
Tatyana Feldman, M.D., Attending, Lymphoma
40 cutting-edge studies at the annual American Society of Hematology Meeting,
Anthony Mato, M.D., Attending, Lymphoma
including multicenter, international trials in collaboration with leading cancer
Pritish Bhattacharyya, M.D., Pathology, Lymphoma
institutions, such as the National Cancer Institute (NCI), MD Anderson, Dana-Farber,
Kar Chow, M.D., Pathology, Lymphoma
Mayo Clinic, and Memorial Sloan-Kettering. Xiao Yang, M.D., Ph.D., Pathology, Lymphoma
Anthony Ingenito, M.D., Chairman, Radiation Oncology
Led by internationally renowned clinician and researcher Dr. Goy, the Lymphoma Division is dedicated to
Blood and Marrow Stem Cell Transplantation treating cancers of the lymphatic system, including Hodgkin lymphoma and non-Hodgkin lymphoma and
serious blood disorders such as amyloidosis.
Scott Rowley, M.D., F.A.C.P., Chief, Blood and Marrow Stem Cell Transplantation Program
Michele Donato, M.D., Medical Director, Blood and Marrow Collection Facility • Participates in groundbreaking research • Dr. Goy is a member of the Lymphoma Research
David Vesole, M.D., Ph.D., Co-Chief and Director, Research, Multiple Myeloma funded by the Susan Vaughan Foundation for Foundation’s Scientific Advisory Board, which
Andrew Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor and Vice President of Cancer Services Translational Research in Lymphoma, the FDA, is comprised of the world’s leading lymphoma
and several pharmaceutical companies. researchers and oncologists.
One of the nation’s 10 largest adult Blood and Marrow Stem Cell Transplant programs, performing more than
• Dr. Goy is widely known for his work as • Collaborates with the Lymphoma Research
300 transplants last year and more than 4,000 total.
co-principal investigator on the PINNACLE trial, Foundation to present the latest practices in the
which led to the FDA’s approval of VELCADE® diagnosis and management of lymphoma.
• More than 30 clinical trials underway, including lymphoma (non-Hodgkin, Hodgkin) as well as (bortezomib) for a defined group of mantle cell
multicenter studies in collaboration with the myelodysplastic and myeloproliferative disorders lymphoma patients.
NCI and National Marrow Donor Program. and hemoglobinopathies (sickle cell anemia).
• Dr. Goy took part in the original pilot study for
• Part of the Bone Marrow Transplant Clinical Trials • Extensive experience in stem cell transplant RITUXAN® (rituximab), which doctors have
Network and Eastern Cooperative Oncology Group, therapy for multiple myeloma. widely used to treat lymphomas, leukemias,
allowing us to collaborate on national clinical trials. • Performs more photopheresis procedures than and autoimmune disorders.
• Clinical trials cover multiple areas: leukemia any transplantation program in the country.
(AML, ALL, CLL, CML), plasma cell dyscrasias
(myeloma, amyloidosis, Waldenstrom’s),
7. “I would have gone anywhere to get the best possible treatment, but I found
Multiple Myeloma it right here in Hackensack. My friends and family didn’t have to travel into
David Siegel, M.D., Ph.D., Chief, Multiple Myeloma New York City during my lengthy hospital stay and the care I received was first-rate.”
David Vesole, M.D., Ph.D., Co-Chief and Director, Research, Multiple Myeloma —Julie Mott, leukemia survivor and 8th person in the world to survive
Joshua Richter, M.D., Attending, Multiple Myeloma a liver transplant and stem cell transplant
One of the few facilities in the U.S. to provide specialized expertise in multiple myeloma, primary systemic
amyloidosis and Waldenstrom’s macroglobulinemia, offering new and emerging therapies that enhance the
quality and extend the life of patients with plasma cell disorders.
Leukemia
• Member of the Multiple Myeloma Research today, including VELCADE® (bortezomib), REVLIMID®
Consortium (MMRC), a unique research model (lenalidomide), Pomalidomide, and Carfilzomib. Stuart Goldberg, M.D., Chief, Leukemia
consisting of 16 institutions to accelerate the Pritish Bhattacharyya, M.D., Pathology, Leukemia
• Our researchers joined colleagues from 20 institutions
development of novel, cutting-edge multiple Kar Chow M.D., Pathology, Leukemia
to publish the first complete genomic portrait of
myeloma treatments. Anthony Ingenito, M.D., Chairman, Radiation Oncology
multiple myeloma.
• Dr. Siegel and Dr. Vesole are two of the The Leukemia Division uses a variety of treatment options, including chemotherapy and stem cell
• A leader in innovative stem cell transplant modalities
foremost international authorities in multiple transplantation, to ensure patients receive the best care available.
for the treatment of multiple myeloma.
myeloma, frequently published in top-tier
peer-reviewed medical journals such as Journal • Active in clinical trials that led to FDA approval • Partners with multiple patient supports groups,
of Clinical Oncology, Blood, Lancet Oncology, of GLEEVEC® (imatinib mesylate) and a new such as the Leukemia & Lymphoma Society, to
and The New England Journal of Medicine. indication for Tasigna® (nilotinib). host educational events and to provide important
Multiple Myeloma programs for patients and their loved ones as well
• Participated in landmark research that has Research Consortium • Dr. Goldberg is internationally recognized for his
led to the approval of some of the most as for health care professionals.
Powerful Collaboration Accelerates Results research in leukemia and other blood cancers.
significant multiple myeloma therapies used In April 2010, he led research published in the
Journal of Clinical Oncology, which concluded
myelodysplastic syndromes blood cancer is five
“When I was diagnosed with multiple myeloma, they told me I had up to times more common than previously thought.
three years to live. Thanks to access to the latest clinical trials and great
personnel, I have spent the last 17 years traveling the world and
watching my grandchildren become adults.”
—George Chambers, 17-year multiple myeloma survivor
8. “I was diagnosed with a brain tumor when I was four months pregnant.
Neuro-Oncology: The Brain and Spine Institute It wasn’t certain that the entire tumor could be removed, but Dr. Kaptain took on
Samuel A. Goldlust, M.D., Co-Chief, The Brain and Spine Institute my case and I’ve been in remission for five years. It is nothing short of a miracle.”
George Kaptain, M.D., Co-Chief, The Brain and Spine Institute —Antonia Reyes, brain cancer survivor
Hooman Azmi, M.D., Neurosurgeon, The Brain and Spine Institute
Mark Pascal, M.D., Neuro-oncologist, The Brain and Spine Institute
David Panush, M.D., Section Head, Neuroradiology, Diagnostic Radiology
Anthony Ingenito, M.D., Chairman, Radiation Oncology Skin and Sarcoma: Cutaneous Malignancy Program
In 2011, the John Theurer Cancer launched the Brain and Spine Institute to coordinate multi-disciplinary Andrew Pecora, M.D., F.A.C.P., C.P.E., Chief Innovations Officer, Professor and Vice President of Cancer Services,
cutting edge care and research for primary and metastatic brain tumors as well as the neurological and Chief, Cutaneous Malignancy Program
complications of cancer. Donald McCain, M.D., Ph.D., Vice Chairman and Chief, Surgical Oncology, Cutaneous Malignancy Program
James Wittig, M.D., Chief, Sarcoma Cancer and Chief, Orthopedic Oncology
• Led by neuro-oncologist Dr. Goldlust, who • One of only 20 facilities in the U.S. to offer Robin Ashinoff, M.D., Chief, Dermatologic, Mohs and Laser Surgery
recently joined from Memorial Sloan-Kettering MRI-guided laser interstitial thermal therapy, a Richard Winters, M.D., F.A.C.S, Vice-Chairman, Plastic and Reconstructive Surgery
Cancer Center and neurosurgeon Dr. Kaptain, novel technology that allows for precision removal
Anthony Ingenito, M.D., Chairman, Radiation Oncology
who has subspecialty training both in neuro- of tumors that may otherwise be inoperable.
oncology and skull-base surgery. • Advanced imaging capabilities include diffusion Provides a multidisciplinary team of leading experts in Mohs surgery, dermatopathology, dermatology, medical
• Multidisciplinary team includes experts in tensor imaging, an MRI technique that allows oncology, oncologic surgery, radiation oncology, reconstructive surgery and research. Our program treats all stages
neurology, neurosurgery, medical oncology, precision mapping of neural pathways in the brain. of malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and other cutaneous malignancies.
radiation oncology, behavioral health, With this and other related imaging modalities,
neuroradiology, otolaryngology, pathology, our physicians are able to minimize harm to • One of the largest surgical melanoma practices • Involved in the landmark study that led to the
and nursing. normal tissues during treatment. in New Jersey, conducting more lymphatic cases FDA’s fast track and approval of YERVOY™
• Research is focused upon developing novel • The Annual Neuro-Oncology Symposium brings than any other in the state. (ipilimumab), a breakthrough treatment for
therapeutics for primary and metastatic brain together world renowned experts to discuss recent • One of the only cancer centers in New Jersey metastatic melanoma.
tumors, improving care for tumor-related breakthroughs and trends in the field. with a dermatopathologist on the staff. • Extensive experience in limb-sparing surgery for
epilepsy, and developing strategies for shoulder girdle tumors, cryosurgery, radiofrequency
neuro-protection in cancer patients. • Extensive expertise in Mohs micrographic surgery,
a specialized procedure that has the highest cure ablation, and minimally invasive biopsies.
rate of all surgical treatments for basal cell and
squamous cell carcinoma.
9. Gastrointestinal Oncology Head and Neck Oncology
Andrew Jennis, M.D., Co-Chief, Gastrointestinal Oncology Loren Godfrey, M.D., Co-Chief, Head and Neck Oncology and Director, Brachytherapy
Donald McCain, M.D., Ph.D., F.A.C.S., Vice Chairman and Co-Chief, Gastrointestinal Oncology Brian Benson, M.D., Co-Chief, Head and Neck Oncology
Anthony Ingenito, M.D., Chairman, Radiation Oncology
Our specialized team is dedicated to preventing, diagnosing, treating, and managing cancers of the head and
Our team of more than 20 experts in gastroenterology, surgery, medical oncology, radiation oncology, neck, including cancers of the mouth, throat, tongue, thyroid, and sinuses.
radiology, pathology and nursing is dedicated to cancers of the gastrointestinal system. Our team offers
innovative treatments and surgical approaches to improve outcomes and decrease recovery time. • Brings together experts in otolaryngology • Hosts annual Head and Neck Cancer Forum that
(ear, nose, and throat medicine), plastic and provides support, networking, and information.
• Extensive expertise with the da Vinci® robotic home earlier and recover faster compared to reconstructive surgery, medical oncology, • Active research in radiation approaches to improve
surgery system for minimally invasive, precise open procedures. maxillofacial surgery, dentistry, radiation outcomes and quality of life for head and neck
surgeries. oncology, radiology, and nursing. cancer patients.
• Open and robotic colon resections, where
• Endoscopic ultrasound for early detection of a part or the entire colon is removed.
gastrointestinal diseases. • Extensive experience treating primary and
• Experts in laparoscopic liver resections, a metastatic liver tumors with hepatic resections Thoracic Oncology
surgical technique that allows patients to go and radiofrequency ablation.
Bernard Park, M.D., Co-Chief, Thoracic Oncology
Harry Harper, M.D., Co-Chief, Thoracic Oncology
Anthony Ingenito, M.D., Chairman, Radiation Oncology
Geriatric Oncology One of only a handful of cancer centers in New Jersey with a full-time multidisciplinary thoracic oncology
team, specializing in the diagnosis and treatment of lung cancer, esophageal cancer, malignant mesothelioma,
Richard Rosenbluth, M.D., Chief, Geriatric Oncology mediastinal tumors, and other cancers within the chest.
This is the first dedicated program designed for senior cancer patients in New York and New Jersey. • One of the most active thoracic oncology lobectomy, a minimally invasive procedure that
clinical trial sites in New Jersey. can decrease recovery time, using the da Vinci™
• A focus on the unique needs, treatment, and • Operates an active pain-management program surgical system.
recovery of patients age 65 and older. and extensive palliative care services that address • Internationally recognized leaders in minimally
end-of-life issues and attempt to ease pain and invasive surgical approaches to thoracic cancer • Employing advanced diagnostic techniques such as
discomfort for patients. treatment. endobronchial ultrasound (EBUS) and navigational
• Dr. Park is one of the original innovators in bronchoscopy.
robotic video-assisted thoracic surgery (VATS)
10. “The yoga classes have helped improve my breathing, relaxation, and flexibility.
More importantly, it shows me that the doctors and staff don’t just want to Urologic Oncology
treat my cancer – they truly care about my total well-being.” Ihor Sawczuk, M.D., Co-Chief, Urologic Oncology and Chairman, Department of Urology
—Bimla Shukla, breast cancer patient Robert Alter, M.D., Co-Chief, Urologic Oncology
Glen Gejerman, M.D., Co-Chief, Urologic Oncology and Director, Radiation Oncology
This multidisciplinary team, which includes some of world’s leaders in urologic oncology, is dedicated to
Radiation Oncology cancers of the genitourinary system, including kidneys, adrenal glands, ureters, bladder, prostate gland, testes,
and male genitalia.
Anthony Ingenito, M.D., Chairman, Radiation Oncology
Glen Gejerman, M.D., Co-Chief, Urologic Oncology and Director, Radiation Oncology • Uses the most advanced diagnostic and • Most experienced TomoTherapy® radiation center
Loren Godfrey, M.D., Co-Chief, Head and Neck and Director, Brachytherapy treatment methods available, including in New Jersey for prostate cancer, which is one of
minimally invasive, laparoscopic, TomoTherapy ®, the most effective radiation methods for targeted
Provides the most advanced radiation therapy treatment methods and a dedicated team of on-site radiation robotic surgical procedures, and cryosurgery. prostate cancer treatment.
oncologists with disease-specific expertise.
• First cancer center in New Jersey to offer • Robotic surgery training site for the northeast.
the complete capabilities of breakthrough
• A multidisciplinary team including board- therapy, and the only cancer center in the country • Ranked number one in New Jersey by Healthgrades
immunotherapy Provenge® (sipuleucel-T)
certified radiation oncologists, medical to acquire two machines. for prostatectomy.
physicists, technologists, radiation therapists, treatment. Prostate cancer patients can receive
• Most experienced cancer center to offer a cell-collection process and infusion by a single • Active in clincial trials for prostate, renal and
medical dosimetrists, certified medical bladder cancer.
TomoTherapy®, treating prostate, lung, and head team, allowing for a more intimate, comforting
assistants, social workers, and registered
and neck cancer with unparalleled accuracy, course of treatment.
dietitians.
precision, and safety.
• Accredited by the American College of • The largest high-dose-rate (HDR) brachytherapy
• Active in clinical trials, with research in new center in the tri-state area, which allows
Radiation Oncology.
approaches such as brachytherapy, Dose physicians to deliver precise radiation treatment
• Safety program ranked above the 95th Verification System® (DVS), and TomoTherapy ®. directly to a tumors.
percentile by the American College of • Implants a breakthrough radiation measurement
Radiology, and patient satisfaction scores are technology, known as DVS®, which provides data
also ranked in the 95th percentile or greater
on the amount of radiation delivered to tumors and
compared to peers. surrounding tissue.
• First cancer center in New Jersey to acquire • Above-ground radiation facility.
TrueBeam™, which enables a radically different
approach to treating cancer with image-guided
11. Women’s Health Oncology Services
We offer a depth of expertise that has propelled our women’s health center to a
Gynecologic Oncology
Donna McNamara, M.D., Co-Chief, Gynecologic Oncology
leadership role in the national fight against cancers specific to women.
Babak Litkouhi, M.D., Co-Chief, Surgical Gynecologic Oncology
Ami Vaidya, M.D., Director, Gynecologic Robotic Surgery
Breast Oncology Loren Godfrey, M.D.,Radiaton Oncologist, Gynecologic Oncology
Stanley Waintraub, M.D.,Co-Chief, Breast Oncology The Gynecologic Oncology Division provides our female patients with extraordinary care from leading
Mary Jane Warden, M.D., Acting Co-Chief, Breast Oncology physicians who understand the unique challenges of women battling cancer.
Loren Godfrey, M.D.,Radiaton Oncologist, Breast Oncology
• Access to multiple clinical trials in ovarian, • Experts in minimally invasive surgical options,
Our Breast Oncology Division is one of only a handful of facilities in New Jersey to offer the most uterine, and cervical cancers, including national including laparoscopic and robotic surgery.
innovative treatment options delivered by an integrated, prominently trained group of highly specialized trials led by the Gynecologic Oncology Group, • One of few centers skilled in both intracavitary
breast cancer experts. a cooperative cancer research group funded by and interstitial high-dose-rate gynecologic
the NCI. brachytherapy techniques – advanced cancer
• Access to multiple clinical trials in breast cancer, • Offers partial breast irradiation using MammoSite® • One of only 20 centers in the country selected treatments that deliver precise radiation directly
including national trials led by the Cancer and targeted radiation therapy, which reduces to train physicians for the revolutionary into tumors, typically on an outpatient basis.
Leukemia Group B and Eastern Cooperative treatment from six weeks to five days for da Vinci® surgical robot, which makes
Oncology Group, as well as access to new many patients. gynecologic cancer surgery easier and safer.
Phase I drugs. • Each year, we invite leading breast oncologists to
• One of the largest clinical trial sites for present the latest research findings to physicians
Herceptin® (trastuzumab), a drug that changed and health care professionals so they can apply
the landscape for breast cancer care. these learnings to the clinic.
The Maureen Fund is a community-education
outreach program that provides ovarian cancer
screenings and prevention services for women.
The Angels of Hope Foundation has created a comforting environment on
the Women’s Health floor, with a beautiful waiting area to help patients feel
at ease prior to their appointments. Their generous donations also provide
services for women with cancer who otherwise could not afford them.
www.aoh-nj.org
12. research Extraordinary Care Means Cutting-Edge Research
Andre Goy, M.D., M.S., Chairman and Director, Chief, Lymphoma and Director, Clinical and Translational Cancer Research
Robert Korngold, Ph.D., Chairman, Research
Martin Gutierrez, M.D., Director, Drug Discovery/Phase 1 Unit
We have been conducting bench to bedside research for more than two decades. Today, a large part of our
research is supporting personalized medicine and targeted therapies that we believe can help researchers
and clinicians improve outcomes. We have established relationships with cooperative research groups and the
pharmaceutical and biotech industry to help bring innovative and translational drugs from Phase I and Phase II
trials into the clinic for the benefit of our cancer patients and patients around the globe.
• More than 200 open, actively enrolling • Phase I Clinical Oncology program with an
clinical trials and a strong translational outpatient clinic and a dedicated inpatient
research program. bed facility.
• Leading multicenter, international trials • The Tumor Bank has collected more than 2,000
in collaboration with other cancer institutions, high-quality specimens to advance cancer research.
such as the NCI, MD Anderson, Dana-Farber, • Participates in a unique partnership with the
Mayo Clinic, and Memorial Sloan-Kettering. National Cancer Institute to establish a joint
• More than 120 peer reviewed publications clinical research program to develop innovative
published in the last four years to advance immunology-based translational research
cancer research. approaches around bone marrow transplantation.
• Part of the Bone Marrow Clinical Trials • Immunology laboratory leads cutting-edge
Network, Eastern Cooperative Oncology stem cell research focused on improving allogeneic
Group, and Multiple Myeloma Research bone marrow transplant by mitigating the effects
Consortium allowing us to collaborate on of Graft vs. Host Disease.
national clinical trials. • Clinical trial site for many breakthrough
• One of few sites in New Jersey to offer therapies, such as VELCADE® (bortezomib),
Search For Clinical Trials molecular staging and classification
capabilities.
GLEEVEC® (imatinib mesylate), Tasigna®
(nilotinib), Provenge® (sipuleucel-T), Herceptin®
(trastuzumab), Avastin® (bevacizumab), YERVOY™
jtcancercenter.org/clinical_trials (ipilimumab).
JTCCResearch@humed.com
13. Celebrating Life and Liberty
Every year, we celebrate with all of our patients and their loved ones at Liberty State Park.
This September, more than 2,200 people joined us and we hope this celebration continues to grow.
John Theurer Cancer Center at Hackensack University Medical Center
92 Second Street, Hackensack, NJ 07601 • 201-996-5900
jtcancercenter.org